Clinical effect of recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein combined with sodium hyaluronate intra-articular injection in the treatment of rheumatoid arthritis
Sun Xiaocong, Ma Hongling, Zhao Juan, Li Yaqi, Xu Zhipeng, Wang Xiaoying, Chen Min
Published 2019-12-01
Cite as Chin J Prim Med Pharm, 2019,26(23): 2822-2825. DOI: 10.3760/cma.j.issn.1008-6706.2019.23.002
Abstract
ObjectiveTo investigate the clinical efficacy of recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein combined with sodium hyaluronate in the treatment of rheumatoid arthritis (RA).
MethodsForty adult RA patients (12 males, 28 females) aged from 36 to 79 were selected in Department of Rheumatology of the Second People′s hospital of Datong from February 2016 to February 2018.The patients were randomly divided into the observation group and the control group according to the digital table, with 20 cases in each group.The observation group was treated by intra-articular injection of recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein and sodium hyaluronate, and the control group was only treated with recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein.The joint swelling, joint pain, joint mobility, morning stiffness, X-ray grade and total effective rate of the two groups were statistically analyzed before and after treatment.
ResultsBefore treatment, there were no statistically significant differences in joint swelling, joint pain, joint mobility, morning stiffness, clinical score and X-ray grade between the two groups (all P>0.05). After treatment, the symptoms and signs of the two groups were obviously improved.The joint pain, joint pressure pain, joint activity, morning stiffness and clinical score in the observation group were (1.2±1.2)points, (0.8±0.7)points, (0.5±0.4)points, (0.7±0.7)points and (4.5±2.6)points, respetively, which were significantly better than those in the control group [(2.2±1.4)points, (1.5±0.9)points, (1.5±0.9)points, (1.5±0.6)points and (8.6±4.6)points, U=125, 111, 68, 89 and 97, all P<0.05]. The total effective rate of the observation group was 100% (20/20), while that of the control group was 75% (15/20), there was statistically significant difference between the two groups (χ2=14.10, P<0.01).
ConclusionThe injection of recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein combined with sodium hyaluronate in the treatment of RA can effectively improve the clinical symptoms of RA patients, and it is more effective than single use.It is worthy of popularizing in clinic.
Key words:
Arthritis, rheumatoid; Tumor necrosis factor receptor-associated peptides and proteins; Hyaluronic acid; Injections, intra-articular; Randomized controlled trial
Contributor Information
Sun Xiaocong
Department of Rheumatology, the Second People′s Hospital of Datong, Datong, Shanxi 037000, China
Ma Hongling
Zhao Juan
Li Yaqi
Xu Zhipeng
Wang Xiaoying
Chen Min
